Cochlear (ASX:COH)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Cochlear Charts. Click Here for more Cochlear Charts.](/p.php?pid=staticchart&s=ASX%5ECOH&p=8&t=15)
AMI Semiconductor (NASDAQ:AMIS), a leading designer and manufacturer of
state-of-the-art integrated mixed-signal and structured digital products
for the automotive, medical and industrial markets, today announced that
Cochlear Limited (ASX:COH), the worldwide leading designer and
manufacturer of cochlear implants for hearing loss, has selected AMIS as
its semiconductor co-design and manufacturing partner for its future
generation DSP-based system-on-chip.
Cochlear implants are a proven treatment for severe-to-profound hearing
loss in adults and children. The surgically implanted electronic device
bypasses damaged hair cells and stimulates the hearing nerve fibres
directly inside the cochlea, providing useful hearing and improved
communication abilities to the wearer. External components include a
sound processor and transmitter that relay processed signals to the
implant using electromagnetic induction. Placed under the skin behind
the ear, the implanted components include a receiver and an
electrode-array that is placed into the cochlea to stimulate precise
locations on the auditory nerve.
Cochlear Limited’s current generation Nucleus
Freedom™ system was approved by the U.S. Food
and Drug Administration (FDA) in March 2005 and is implanted in over
12,000 patients worldwide.
“Technical leadership and continually
advancing the hearing performance, reliability and usability of our
devices is fundamental to our strategy,” said
Jan Janssen, senior vice president of design and development at
Cochlear. “With proven expertise in advanced
mixed-signal technologies, deep knowledge of audiological technical
requirements and a solid body of existing semiconductor IP, we chose AMI
Semiconductor as a technology partner. We believe that with the help of
AMIS, we will introduce new capabilities, offering an enhanced quality
of life for people with severe to profound hearing loss.”
“We are thrilled to form a technology
partnership with Cochlear. Their track record of innovation is truly
impressive,” said Todd Schneider, vice
president of the medical group at AMIS. “Cochlear
implants continue to be the largest segment of the neural prostheses
category of neurostimulation medical devices and an area where we’ve
developed specific expertise and innovative solutions. This relationship
reinforces our belief that customers value a dependable and highly
flexible partner dedicated to meeting the specific semiconductor needs
of the medical device market.”
About AMI Semiconductor
AMI Semiconductor (AMIS) is a leader in the design and manufacture of
silicon solutions for the real world. As a widely recognized innovator
in state-of-the-art integrated mixed-signal and structured digital
products, AMIS is committed to providing customers with the optimal
value, quickest time-to-market semiconductor solutions. Offering
unparalleled manufacturing flexibility and dedication to customer
service, AMI Semiconductor operates globally with headquarters in
Pocatello, Idaho, European corporate offices in Oudenaarde, Belgium, and
a network of sales and design centers located in the key markets of
North America, Europe and the Asia Pacific region.
About Cochlear Limited
Cochlear is the global leader in the development, manufacture and
marketing of innovative implantable hearing solutions. Products include
the Nucleus range of Cochlear implant systems and the Baha implant
system, a bone conduction implant designed to help those with conductive
hearing loss, mixed hearing loss and single sided deafness.
Headquartered in Sydney, Australia, Cochlear is an Australian Stock
Exchange traded public company with over 1100 employees globally.
Additional information about Cochlear can be found at www.cochlear.com.
AMI Semiconductor (NASDAQ:AMIS), a leading designer and
manufacturer of state-of-the-art integrated mixed-signal and
structured digital products for the automotive, medical and industrial
markets, today announced that Cochlear Limited (ASX:COH), the
worldwide leading designer and manufacturer of cochlear implants for
hearing loss, has selected AMIS as its semiconductor co-design and
manufacturing partner for its future generation DSP-based
system-on-chip.
Cochlear implants are a proven treatment for severe-to-profound
hearing loss in adults and children. The surgically implanted
electronic device bypasses damaged hair cells and stimulates the
hearing nerve fibres directly inside the cochlea, providing useful
hearing and improved communication abilities to the wearer. External
components include a sound processor and transmitter that relay
processed signals to the implant using electromagnetic induction.
Placed under the skin behind the ear, the implanted components include
a receiver and an electrode-array that is placed into the cochlea to
stimulate precise locations on the auditory nerve.
Cochlear Limited's current generation Nucleus Freedom(TM) system
was approved by the U.S. Food and Drug Administration (FDA) in March
2005 and is implanted in over 12,000 patients worldwide.
"Technical leadership and continually advancing the hearing
performance, reliability and usability of our devices is fundamental
to our strategy," said Jan Janssen, senior vice president of design
and development at Cochlear. "With proven expertise in advanced
mixed-signal technologies, deep knowledge of audiological technical
requirements and a solid body of existing semiconductor IP, we chose
AMI Semiconductor as a technology partner. We believe that with the
help of AMIS, we will introduce new capabilities, offering an enhanced
quality of life for people with severe to profound hearing loss."
"We are thrilled to form a technology partnership with Cochlear.
Their track record of innovation is truly impressive," said Todd
Schneider, vice president of the medical group at AMIS. "Cochlear
implants continue to be the largest segment of the neural prostheses
category of neurostimulation medical devices and an area where we've
developed specific expertise and innovative solutions. This
relationship reinforces our belief that customers value a dependable
and highly flexible partner dedicated to meeting the specific
semiconductor needs of the medical device market."
About AMI Semiconductor
AMI Semiconductor (AMIS) is a leader in the design and manufacture
of silicon solutions for the real world. As a widely recognized
innovator in state-of-the-art integrated mixed-signal and structured
digital products, AMIS is committed to providing customers with the
optimal value, quickest time-to-market semiconductor solutions.
Offering unparalleled manufacturing flexibility and dedication to
customer service, AMI Semiconductor operates globally with
headquarters in Pocatello, Idaho, European corporate offices in
Oudenaarde, Belgium, and a network of sales and design centers located
in the key markets of North America, Europe and the Asia Pacific
region.
About Cochlear Limited
Cochlear is the global leader in the development, manufacture and
marketing of innovative implantable hearing solutions. Products
include the Nucleus range of Cochlear implant systems and the Baha
implant system, a bone conduction implant designed to help those with
conductive hearing loss, mixed hearing loss and single sided deafness.
Headquartered in Sydney, Australia, Cochlear is an Australian Stock
Exchange traded public company with over 1100 employees globally.
Additional information about Cochlear can be found at
www.cochlear.com.